Typhoid Fever Market
According to DataM Intelligence, the global Typhoid Fever Market is undergoing significant evolution, driven by increasing access to vaccines, diagnostics, and public health efforts. The disease remains a critical public health challenge in low- and middle-income countries, but market expansion is being shaped by government vaccination campaigns, pipeline drugs, and better diagnostic infrastructure.
Download exclusive insights with our detailed sample report (Corporate Email ID gets priority access): https://www.datamintelligence.com/download-sample/typhoid-fever-market?ophp
The market was valued at USD 332.4 million in 2023 and is projected to grow at a CAGR of 4.9% over the forecast period (2024-2031), as per DataM Intelligence.
📈 Market Segments Overview
• By Drug Class:
o Antibiotics dominate the segment, particularly azithromycin and ceftriaxone, although rising resistance is driving demand for alternative therapies.
o Vaccine Segment is growing fastest due to WHO-prequalified Typhoid Conjugate Vaccines (TCVs), especially in India and Africa.
• By Diagnosis:
o Widal Tests continue to hold the highest market share in low-resource settings.
o However, Rapid Diagnostic Tests (RDTs) and molecular diagnostics are gaining popularity, especially in urban centers.
• By End User:
o Hospitals are the largest users, but government-run vaccination programs and NGOs are contributing to expanding outreach.
Looking for in-depth insights? Grab the full report: https://www.datamintelligence.com/buy-now-page?report=typhoid-fever-market?ophp
Key Players in the Market
• Bharat Biotech – manufacturer of Typbar TCV
• GlaxoSmithKline – involved in typhoid vaccine R&D
• Sanofi Pasteur – offers injectable vaccines in endemic markets
• Pfizer Inc. – pursuing innovative oral formulations
• Emergent BioSolutions – working on public-private partnerships for vaccine deployment
• Bio-Manguinhos/Fiocruz (Brazil) – distributing vaccines through Latin America
• Micropoint Bioscience – developers of portable typhoid diagnostic kits
Latest News from Japan (2025)
In June 2025, Japan’s Ministry of Health announced a funding grant of ¥3.5 billion (approx. USD 23 million) to the University of Tokyo and National Institute of Infectious Diseases for a new vaccine delivery platform. This initiative will test thermostable typhoid conjugate vaccines (TCVs) for better storage in tropical climates, aiming to partner with the WHO COVAX facility for low-income nations.
Additionally, Fujifilm Toyama Chemical initiated early-stage development of a broad-spectrum antimicrobial candidate targeting resistant typhoid strains, with pre-clinical trials set for late 2025.
Latest News from the United States (2025)
In May 2025, the U.S. Agency for International Development (USAID) increased its funding for waterborne disease surveillance in sub-Saharan Africa by USD 60 million, with a dedicated focus on typhoid and cholera. The initiative will deploy mobile diagnostic labs equipped with U.S.-developed PCR testing kits.
Simultaneously, Johns Hopkins University began Phase I trials on a next-gen oral typhoid vaccine, expected to be more tolerable and require fewer booster doses.
Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/typhoid-fever-market?ophp
Trends and Opportunities
• Vaccine Innovation: Growing demand for single-dose conjugate vaccines is driving R&D partnerships between pharma companies and public health agencies.
• Point-of-Care Diagnostics: There’s a surge in demand for low-cost, rapid, and accurate diagnostics in both rural and urban clinics.
• Resistance Concerns: Multidrug-resistant (MDR) typhoid, especially H58 strain, is creating urgent demand for alternative antibiotics and combination therapies.
• Water Sanitation Infrastructure: Investment in sanitation, clean water, and education is reducing prevalence but remains underfunded in parts of Africa and South Asia.
Challenges Ahead
Despite innovation, several hurdles persist:
• Antibiotic Resistance: Strains resistant to fluoroquinolones and cephalosporins are becoming more prevalent.
• Low Awareness: In remote areas, typhoid symptoms often go undiagnosed or misdiagnosed.
• Cold Chain Dependency: Current vaccines still require temperature-controlled logistics, limiting rural deployment.
• Inequitable Access: High-quality diagnostics and treatment remain unaffordable in many endemic regions.
Conclusion
According to DataM Intelligence, the typhoid fever market is poised for moderate yet sustained growth, fueled by a mix of vaccination initiatives, diagnostic innovation, and public-private partnerships. As the world turns attention toward health equity and AMR (antimicrobial resistance), investments from countries like Japan and the U.S. are shaping a new global strategy-one focused on eradication, not just control.
Unlock 360° Market Intelligence with 2 Days FREE Trial Access of DataM Subscription Now!: https://www.datamintelligence.com/reports-subscription
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Pipeline Analysis For Drugs Discovery
✅ Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Competitive Landscape
Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg
Contact Us –
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us –
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
link